Capricor Therapeutics EBIT

Capricor Therapeutics (CAPR) currently reports a EBIT of $-43B as of June 2026. That compares with $-13B in the prior-year period — down 229.3% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Capricor Therapeutics's EBIT history and peer comparisons.

Capricor Therapeutics's EBIT decreased from $-13B to $-43B — a 229.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Capricor Therapeutics's EBIT of $-43B is lower than the Healthcare sector average of $22B. That is roughly 293.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Capricor Therapeutics reported $-43B in EBIT as of June 2026. That compares with $-13B in the prior-year period — down 229.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-43B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Capricor Therapeutics, and consider following CAPR for alerts when major investors trade the stock.